



May 13, 2025

Press Release

Eiken Chemical Co., Ltd.
Representative: Tsugunori Notomi,
President & CEO
Securities code: 4549 (TSE Prime Market)

Notice Concerning Transfer of Equity Interests of Consolidated Subsidiaries

Our company hereby announces that its Board of Directors meeting held today resolved to transfer all equity interests in EIKEN CHINA CO., LTD. (Hereinafter, "Eiken China"), our company's consolidated subsidiary engaged in manufacturing and sales of clinical diagnostics as follows.

1. Reason for transfer of equity interest

Since its establishment in 2004, Eiken China has contributed to the reduction of manufacturing costs in our group by processing raw materials at relatively low labor costs. However, in recent years, especially in Shanghai, labor and raw material transportation costs have soared, and profitability has declined. In addition, due to concerns about various country risks, we reviewed our product portfolio and determined that the transfer of our equity interest in Eiken China will contribute to the enhancement of our company's corporate value, as we will be able to improve production efficiency by concentrating the raw materials processing at Eiken China to the Nogi Division in our company and improve management efficiency by converting into direct sales to our company products sold through Eiken China.

2. Overview of Subsidiary

(1)	Company name	EIKEN CHINA CO., LTD.	
(2)	Company Address	1058 Ha Lei Road, Zhangjiang Hi-Tech Park, Pudong new District, Shanghai, P.R.C.	
(3)	Representative	Chairperson Yasuyoshi Mori	
(4)	Business	Manufacturing and sales of clinical diagnostics	
(5)	Capital	1,205 million US dollars	
(6)	Date founded	September 27, 2004	
(7)	Equity ratio	Our company 100%	
(8)	Relationship between our company and the company	capital relationship	100% owned by our company.
		human relationship	Officers and employees of our company concurrently serve as officers of the company.
		business relationship	We process and produce clinical diagnostics and purchase and manufacture clinical diagnostics.

(9) Business performance and financial position of the company in the last three years			
Period	Fiscal year ended March 2023	Fiscal year ended March 2024	Fiscal year ended March 2025
Net assets	1,116 million yen	1,177 million yen	867 million yen
Total assets	1,168 million yen	1,216 million yen	947 million yen
Net sales	487 million yen	469 million yen	396 million yen
Operating profit	(76) million yen	(47) million yen	(72) million yen
Ordinary profit	(52) million yen	(20) million yen	(45) million yen
Net profit	(52) million yen	(20) million yen	(295) million yen

3. Future Prospects

Negotiations with the potential transferee are in progress and the details have not yet been determined. We will announce the details as soon as an agreement on the transfer is officially concluded between the Company and the transferee.